Bactobio Raises £6 Million To Discover Novel Antimicrobials
Bactobio Ltd (‘Bactobio’ or ‘the Company’), a biotechnology company uncovering safer and greener antimicrobial solutions from previously unexplored microbes, announced that it has closed an oversubscribed £6 million bridge financing round. The financing was led by Bridford Group, with support from angel investors Peder Holk Nielsen (Former CEO and President of Novozymes) and Hugh Grant (Former Chairman and CEO of Monsanto). New investors included the founders of the London-based fintech unicorn Lendable and Entangle Group.
Latest Aithority Insights : Got It AI Announces AutoFlows, a Breakthrough Autonomous Conversational AI
“Today’s raise supports our continued drive towards automation and data-driven science that will help turn our captured biodiversity into commercial products” – Daniel Hansen, CEO and Founder of Bactobio
Bactobio is a world leader in capturing and exploring novel biodiversity.
The Company’s unique combination of synthetic biology, next-generation sequencing and machine learning gives exclusive access to a growing library of thousands of previously unscreened microbes.
An interdisciplinary approach then enables a thorough exploration of the potential chemical space, creating unmatched opportunity for new discovery across markets in healthcare, agriculture and bio-derived chemicals.
Today’s announced funds will be used to advance Bactobio’s pioneering discovery pipeline and enable characterisation of the next generation of antimicrobial solutions.
“With our 2021 fundraise we built a complete end-to-end compound discovery pipeline. Today’s raise supports our continued drive towards automation and data-driven science that will help turn our captured biodiversity into commercial products,” said Dr Daniel Hansen, CEO and Founder of Bactobio. “We are immensely proud to receive such a high level of new and continued support from high calibre investors.”
Dr Mark Wilkinson, CSO at Bactobio, commented “It is estimated that fewer than 3% of the potential natural products encoded in nature have been identified to-date. Bactobio’s bioactivity-driven but target-agnostic approach lets nature do the work and lead us towards compounds which have been unimaginable and previously inaccessible to drug discovery efforts. Funds from this round will allow us to dig deeper into this previously untapped bioresource.”
Latest AI/NLP Technology Insights: ProcessUnity Acquires AI/NLP Technology from ISMS Solutions
[To share your insights with us, please write to email@example.com]